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Take home message 
Emphysema in IPF patients has no effect on outcome beyond that explained by 
combined fibrosis and emphysema extents. 
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Abstract 
To investigate whether the combination of fibrosis and emphysema has an effect 
greater than the sum of its parts on functional indices and outcome in IPF using 
visual and computer-based (CALIPER) CT analysis. 
 
Consecutive patients (n=272) with a multi-disciplinary IPF diagnosis had CT extents of 
interstitial lung disease (ILD) scored visually and by CALIPER. Visually-scored 
emphysema was subcategorized as isolated or mixed with fibrotic lung. CT scores 
were evaluated against functional indices (FVC, DLco, Kco and CPI) and mortality. 
 
The presence and extent of emphysema had no impact on survival. Results were 
maintained following correction for age, gender, smoking status and baseline 
severity using DLco, and combined visual emphysema and ILD extent. Visual 
emphysema quantitation indicated that relative preservation of lung volumes (FVC) 
resulted from tractionally-dilated airways within fibrotic lung ventilating areas of 
admixed emphysema (p<0.0001), with no independent effect on FVC from isolated 
emphysema. Conversely, only isolated emphysema (p<0.0001) reduced gas transfer 
(DLco).  
 
There is no prognostic impact of emphysema in IPF, beyond that explained by the 
additive extents of both fibrosis and emphysema. Emphysema distribution with 
respect to the location of pulmonary fibrosis determines the functional effects of 
emphysema. 
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INTRODUCTION 
Patients with co-existing emphysema form a sizeable proportion of idiopathic 
pulmonary fibrosis (IPF) cohorts, 1-4 a possible consequence of an association with 
smoking pertinent to both diseases.5, 6 A unique phenotype ascribed to patients with 
combined fibrosis and emphysema (CPFE) rested with the identification of a 
worsened survival in patients with CPFE over those with isolated fibrosis. 7-10 The 
basis for a poor outcome has been suggested to be partly related to an increased 
predisposition to developing pulmonary hypertension (PHT). 7, 10, 11 However 
subsequent analyses of CPFE cohorts have provided conflicting data on the survival 
implications of emphysema coexisting with fibrosis 4, 12-15 and the question of 
whether the co-existence of pulmonary fibrosis and emphysema constitutes a 
discreet clinical syndrome remains unresolved. 16, 17 Conflicting CPFE data has also 
led to a belief that CPFE should be viewed as a different disorder from IPF in terms of 
progression to death and this in turn has caused some clinicians to have doubts 
about using anti-fibrotic therapy in CPFE. 
 
A common constraint in the study of CPFE cohorts has been the limited 
quantification of CT emphysema extent, be that by visual or automated means. 
Simply ascertaining the presence or absence of emphysema restricts the precision 
with which a dose-effect of emphysema may be shown to influence survival. 
Similarly, the delineation and quantitation of emphysematous areas admixed within 
fibrotic lung as opposed to emphysematous foci isolated from areas of fibrosis has 
not been definitively examined to date. Yet quantifying emphysematous destruction 
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within areas of fibrosis may inform and improve our understanding of the complex 
physiological effects that result from CPFE.4, 10, 13, 16, 18 
 
In the current study, we therefore quantified the cumulative (morphological or 
functional) extents of emphysema and interstitial lung disease (ILD) in patients with 
IPF, utilizing visual and computer-based CT analysis. Our primary aim was to identify 
whether a unique synergistic effect exists in IPF patients with emphysema, which 
results in a worsened outcome to a degree greater than that expected from the 
cumulative extents of ILD and emphysema. Secondarily we wanted to investigate the 
functional impact of emphysema when it occurs both separate to and within fibrotic 
regions of lung in IPF.  
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METHODS 
Clinical data 
A retrospective analysis of an ILD database identified all consecutive, newly 
attending patients, who on re-analysis received a multidisciplinary team (MDT) 
diagnosis of IPF according to published guidelines, 19 over a four and a half year 
period (January 2007 to July 2011)[n=283]20. Following publication of the INPULSIS 
study21, all patients with a possible UIP CT pattern were re-examined. 4 patients 
were found to have a possible UIP pattern without traction bronchiectasis, whilst 7 
patients had CT findings inconsistent with a UIP diagnosis and no surgical lung 
biopsy. Accordingly, following exclusion of these 11 patients, the final study 
population was 272 IPF patients. All patients had a departmental, non-contrast, 
supine, volumetric CT.  
 
CT, pulmonary function test protocols and CALIPER data processing steps are 
included in the supplementary appendix. The study population has been previously 
described in two studies 20, 22. Approval for this retrospective study of clinically 
indicated CT and pulmonary function data was obtained from the institutional ethics 
committee and informed patient consent was not required.  
 
CT evaluation 
CALIPER evaluation was performed as previously described and scores of ILD and 
emphysema extent and pulmonary vessel volume (PVV) were considered in the 
analyses.22 CTs were visually scored on a lobar basis with extents of ILD, emphysema 
and honeycombing estimated to the nearest 5%. Traction bronchiectasis 23 was 
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assigned on a lobar basis with a categorical “severity” score as previously described. 
22 Calculation of admixed and isolated emphysema extents are explained in the 
supplementary appendix.  
 
Development of the modeling strategy  
In all analyses, adjustment was made for patient age, gender and smoking status. 
When analyses were re-examined unadjusted, cardinal results did not change. Visual 
emphysema scores were found to be clearly superior to CALIPER emphysema scores 
as described in the Supplemenatry Appendix. Therefore in all subsequent analyses, 
visual emphysema scores were taken as the primary measure of emphysema. When 
the ILD score that best complimented visual emphysema was examined against our 
co-primary end points (mortality and relationships to baseline DLco), CALIPER ILD 
extent was only marginally stronger than visual ILD scores at mortality prediction 
(Table 6 and Supplementary Table 3). Both ILD measures were therefore used in all 
subsequent analyses to ensure than conclusions reached when using CALIPER in the 
model were robust when visual ILD was substituted.  
 
Three separate indices were used to adjust for baseline disease severity in all 
mortality analyses. The first index was functional, namely DLco. The other two 
indices were morphological. To enable the evaluation of an extra-effect of CPFE on 
disease progression in excess of that expected from a combination of fibrosis and 
emphysema, the combined severity of emphysema and ILD was captured by 
summing visual emphysema extent scores with ILD extent scores to create two 
indices of parenchymal damage: CILDemph=CALIPER ILD extent + Visual emphysema 
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extent; VILDemph=Visual ILD extent + Visual emphysema extent. On linear regession 
analyses, there was a complete absence of colinearity between visual emphysema 
presence and CILDemph or VILDemph. 
 
Statistical analysis 
Data are given as medians or means with standard deviations depending on 
distributions, or numbers of patients with percentages where appropriate. 
Differences between groups were evaluated using a Chi-squared test for categorical 
variables or a two-sample T test for parametric continuous variables. Statistical 
significance was evaluated at a value of p<0.05. Linear regression analyses were used 
to identify relationships between CT and functional indices, and PVV and 
emphysema. Univariate and multivariate Cox regression analyses were used to 
investigate variables predictive of mortality. Survival estimation was performed via 
the Kaplan Meier method. Two-sample survival comparisons were performed using 
the Log rank test. Assumptions of linearity and proportional hazards were tested by 
visual inspection of Martingale residuals and scaled Schoenfeld residuals and were 
satisfied. Statistical analyses were performed with STATA (version 12, StatCorp, 
College Station, TX, USA).  
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RESULTS 
Demographic data 
272 patients diagnosed with IPF (Supplementary Figure 1) had vital status completed 
on 268/272 (99%) cases with 4 patients lost to follow up. 55/272 (20%) cases had 
biopsy confirmation of the diagnosis. No difference in patient age or gender was 
identified between patients with and without emphysema. Patients with 
emphysema were significantly more likely to develop lung cancer however. 
Demographic details for patients with and without visually scored emphysema are 
shown in Table 1. The single determination standard deviation for the visual 
emphysema scores was 4.80 (Supplementary Table 2).24 The kappa value for 
interobserver variation scoring of the presence of emphysema was 0.59. 
 
Characterization of the CPFE pulmonary function phenotype 
The presence of emphysema was associated with a relative preservation of lung 
volumes (FVC) whilst disproportionately reducing gas transfer (DLco) and the gas 
transfer coefficient (Kco). The results were maintained when emphysema was 
analysed as a continuous extent score (Table 2) and when analysed at thresholds of 
>0%, >5% and >10% of visual emphysema (Table 3). Linkages between ILD and 
emphysema extents and DLco are shown in Supplementary Table 3. The increase in 
FVC with emphysema in multivariate models reflects a relatively diminished FVC 
reduction for a given extent of fibrosis, and does not imply that emphysema causes 
an intrinsic rise in FVC. 
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No relationship was identified between total visual emphysema extent (or its 
isolated and admixed subcategories) with ILD extent scored either visually or by 
CALIPER. The extents of both isolated and admixed emphysema were associated 
with obstructive functional indices as determined by correlations of isolated 
(R2=0.32, p<0.0001) and admixed emphysema (R2=0.14, p<0.0001) with FEV1/FVC 
ratios.  
 
Characterization of functional effects of emphysema location 
Examination of the functional effects of isolated and admixed emphysema 
demonstrated that isolated emphysema was independently associated with lower 
DLco and Kco but had no impact on FVC or VA (Table 4). Admixed emphysema was 
associated with preserved FVC and VA with no independent effect on DLco, and 
opposing effects on VA and Kco (Table 4).  
 
Effects of supervening emphysema on CT markers of fibrosis 
Evaluation of CT determinants of traction bronchiectasis demonstrated that 
emphysema had a negative correlation with traction bronchiectasis whilst ILD extent 
and honeycombing demonstrated positive correlations (Table 5). When isolated and 
admixed emphysema were substituted for total emphysema extent in the same 
model, only admixed emphysema demonstrated a strong negative linkage with 
traction bronchiectasis (Table 5). 
 
The pulmonary vessel volume has been previously shown to strongly predict 
outcome in patients with IPF20, and consequently links between PVV and 
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emphysema were explored. After adjusting for the extent of ILD scored by CALIPER 
(Beta Coefficient=0.08, CI 0.08 to 0.09, p<0.0001), the presence of emphysema (Beta 
Coefficient=-0.31, CI -0.52 to -0.10, p=0.005) was independently associated with a 
minor (6.0%) reduction in PVV (mean PVV=5.13%) with a model R2=0.75. 
 
Impact of emphysema on survival in IPF  
On univariate analysis, when emphysema was evaluated as a continuous variable, a 
binary absence-presence score or as a four-point categorical variable (0=no 
emphysema, 1=0-5% emphysema, 2=5-15% emphysema, >15% emphysema),visually 
scored emphysema did not significantly predict mortality (Table 6). The presence of 
emphysema did not alter outcome on Kaplan-Meier analyses (Figure 2a) with results 
maintained in patients with severe disease (DLco<35% predicted)[Figure 2b].  
 
Emphysema is, on average, much less extensive than pulmonary fibrosis. For this 
reason, there is much less variation in the extent of emphysema than in the extent 
of fibrosis. Therefore, the prognostic value of variation in the extent of emphysema 
is overpowered/confounded in univariate analysis because the highly variable extent 
of associated pulmonary fibrosis is not taken into account. On multivariate analysis 
however (Table 6), visual emphysema (on a four-point scale) was independently 
predictive of mortality when analysed against and adjusted for CALIPER ILD extent. 
Neither isolated nor admixed emphysema extents were predictive of survival 
following correction for global disease extent (using DLco). 
 
Outcome adjusted for summed models of disease severity 
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On univariate mortality analyses, summed CALIPER ILD extent and visual emphysema 
extent (CILDemph) and summed visual ILD extent and visual emphysema extent 
(VILDemph) both strongly predicted outcome (Table 7). CILDemph and VILDemph 
also demonstrated strong linkages with with DLco (R2=0.43, p<0.0001 and R2=0.45, 
p<0.0001 respectively)[Supplementary Table 3].  
 
When separately adjusting for disease severity (using CILDemph, VILDemph and 
DLco), the presence of emphysema did not independently predict mortality (Table 
7), with results maintained in patients with severe disease (DLco<35% predicted)[ 
Supplementary Table 4].  
 
As separate contributors to severity, emphysema and fibrosis both had added 
linkage to mortality. However, once the total extent of disease was summed (as a 
combined fibrosis and emphysema score), it was immaterial (in terms of predicting 
mortality) whether the total extent of disease was due to pulmonary fibrosis alone 
or a combination of pulmonary fibrosis and emphysema. As well as there being no 
evidence that CPFE was greater than the sum of its parts in predicting mortality, no 
link to more progressive disease (as judged by greater mortality for a given extent of 
disease) was identified in CPFE following correction for the combined effects of 
emphysema and ILD. The multivariate analysis was possible only because there was 
very little difference in the total extent of disease whether or not emphysema was 
present and no collinearity between the total extent score and the presence or 
absence of emphysema was present.    
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DISCUSSION  
Our study has shown that in a large consecutive IPF patient cohort, using a 
combination of visual emphysema analysis and computer-based ILD quantitation, 
neither the presence nor the extent of emphysema impacts survival following 
correction for baseline disease severity. For the first time, we have demonstrated 
the opposing effects on pulmonary volumes and gas transfer when emphysema lies 
primarily admixed within areas of fibrosis. We have furthermore demonstrated the 
inverse relationship that exists between admixed emphysema and traction 
bronchiectasis, a validated CT marker of fibrosis. 
 
In past evaluations of IPF patients with emphysema, analysis has concentrated on 
those CPFE patients in whom emphysema is extensive. In the CPFE study by Cottin et 
al 7 patient selection rested on the recollection by clinicians of patients with 
concomitant emphysema and fibrosis. The possibility that a significant proportion of 
these cases had unusually extensive emphysema is suggested by the finding that 
30/61 (49%) patients in their study 7 had an obstructive ventilatory defect (FEV1/FVC 
<70% predicted) compared to the current study where only 2/101 (2%) patients with 
emphysema demonstrated an obstructive defect. Studies have also defined non-
validated emphysema extent thresholds such as >10% of the lung in their CPFE 
inclusion criteria. 4, 10 In the current study only 35/105 (33%) of CPFE patients had an 
extent of emphysema >10% of the lung.  
 
There is little evidence that cohort-wide estimations of the phenomenon of CPFE 
and its impact have been adequately studied. It would seem logical that once 
 15 
population based assessments of emphysema have been made in IPF across the 
range of disease severity, as was the aim of the current study, questions relating to 
useful thresholds for emphysema extent could subsequently be addressed. Indeed 
whilst emphysema thresholds per se may have value, greater importance may lie 
with delineating the predominant pathology in any single patient, namely deciding 
whether emphysema is more extensive in the lungs than fibrosis. In this regard, 
technological advances used in the current study, that were not available to prior 
investigations describing CPFE, may help improve the characterization of both 
emphysema and fibrosis extent. In addition to the utilization of automated CT 
quantitation which can improve on visual CT evaluation of ILD extent,20, 22 we utilized 
volumetric CT acquisitions which allow the visual quantitation of emphysema and 
visual and computer-based quantitation of ILD across the entire lung volume, rather 
than at sampled interspaced levels. 
 
In line with previous reports, in our study, IPF did not progress at a faster trajectory 
when emphysema co-existed. 4, 12 Instead prognosis in CPFE was more heavily 
aligned with baseline disease severity. The continued discordance in fundamental 
outcome measures such as mortality between CPFE reports 4, 7, 10, 12 argues for a 
pressing need for a definition, which doesn't currently exist, of what constitutes 
CPFE. An international initiative to agree on a CPFE definition is clearly warranted to 
curtail a real danger that future studies in CPFE cannot be integrated. 
 
Our study findings provide further confirmation of the unique functional profile that 
occurs when emphysema co-exists with IPF. 4, 7, 10, 13, 18 Emphysema preserves lung 
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volumes, limiting the utility of FVC to act as an index to adjust for baseline disease 
severity in CPFE. CPI is negated in CPFE as it only measures the functional impact of 
fibrosis and not emphysema. It is DLco that represents the cardinal functional index 
in CPFE patients as it reflects the contribution of both interstitial fibrosis and 
emphysema to the reduction of gas exchange. The strength of DLco as a measure of 
disease severity in CPFE was confirmed by the strikingly similar results in our study 
when DLco and indices reflecting cumulative pulmonary damage (summed visual or 
CALIPER ILD and visual emphysema extents) were used to control for baseline 
disease severity. In turn the similarities in analyses between morphological scores 
and DLco validated our chosen methodological approach of combining quantitative 
and visual CT measures. 
 
The clinical observations of the current study were made more robust by the 
utilization of independent methods of scoring ILD extent. Integrating automated and 
visual analysis is valuable, for example in our analyses, we selected those variables 
for which CALIPER is a strength (precision in delineating ILD extent) and those 
variables for which expert visual judgments are a requisite (distinguishing admixed 
emphysema from honeycomb cysts). Had a strategy of utilizing only automated 
scores been adopted in the current study, the distinct functional effects of admixed 
emphysema would not have been discovered. Whilst subjective and, increasingly, 
automated scoring have their proponents, the best model may be a combination of 
both modalities. A recent study by Araki et al25 in a large Framingham Heart study 
cohort elegantly highlighted the constraints that can result when relying solely on an 
automated method of quantitation of interstitial lung abnormalities (ILA’s). The 
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subtle differentiation of minor fibrotic changes as is seen in respiratory bronchiolitis, 
from abnormalities that are more compatible with early IPF such as sub-pleural 
reticular abnormalities are as yet not possible with automated systems and such 
analyses can be enhanced by the addition of visual ILA characterization. 
 
Most studies evaluating emphysema in IPF have been hampered, as previously 
described, by limitations in the CT quantitation of fibrosis and emphysema extents. 4, 
10, 15, 26 Automated quantitation studies meanwhile have been hampered by small 
sample sizes, 8, 27-30 and the challenges of distinguishing emphysema from 
honeycomb cysts or traction bronchiectasis. The challenge of separating emphysema 
from honeycombing by a computer tool remains unmet and was the reason for the 
reliance on visual emphysema scores for emphysema quantitation and 
characterization in the current study analyses.  
 
Uniquely, we have identified that pure and admixed emphysema are associated with 
distinct functional consequences. Admixed emphysema preserved lung volumes 
including FVC and VA, in contrast to isolated emphysema. Emphysema is typically 
associated with air-trapping as a result of airway narrowing and collapse on 
expiration as bullous spaces fail to deflate. 31 In areas of fibrosis however, 
contraction of the interstitial connective tissue framework can pull open small 
airways, 32 visible on CT as traction bronchiectasis, 33 thereby allowing the ventilation 
of emphysematous airspaces with a consequent preservation of FVC and VA. In our 
analyses, a reduction in DLco values was primarily related to the extent of ILD and 
not admixed emphysema. The destruction of capillary beds in areas of isolated 
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emphysema are thought to inhibit gas transfer (DLco), by reducing the blood volume 
within the lungs. However in areas of admixed emphysema, vascular destruction 
may be a consequence of both fibrotic and emphysematous processes. Emphysema 
had a greater impact on Kco than the ILD extent scored visually or by CALIPER, 
reproducing previous findings.1 However preservation of alveolar volume by 
admixed emphysema did influence the gas transfer coefficient, which is synonymous 
with DLco/VA. 
 
The severity of traction bronchiectasis, a cardinal morphological measure of disease 
severity in IPF,20, 34 was found to inversely relate to the extent of emphysema 
(admixed) in the present study in keeping with a previous report. 35 Whilst traction 
bronchiectasis enables bullae to remain ventilated, the emphysema-induced 
parenchymal damage that precedes interstitial fibrosis may limit the degree to which 
airways can be pulled open by a contracted and fibrosed connective tissue scaffold, 
when compared to areas of fibrosis without admixed emphysema. The relative 
reduction in ILD extent in CPFE patients compared to IPF patients in the current 
study are in accordance with previous results 4 and may reflect earlier recognition of 
symptoms of dyspnea, in a patients IPF disease course as emphysema reduces a 
patients functional reserve. 
 
The PVV was shown to be reduced by 6% in IPF patients with emphysema and may 
reflect alveolar and capillary destruction in emphysema36 resulting in reduced 
vascularity quantified by CALIPER within regions of emphysematoid lung. It has also 
been suggested that the high negative intrathoracic pressures required for 
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inspiration in patients with fibrosis may exert a pull on pulmonary vessel walls, and 
thereby result in an increase in the PVV. Consequently, when emphysema co-exists 
with fibrosis, a relative reduction in intrathoracic pressures may result in a slight 
reduction in the PVV when compared to patients with fibrosis alone.  
 
In our study, when correcting for the visual extent of emphysema and at thresholds 
of >5% and >10% visual emphysema, smoking status had an independent effect on 
pulmonary function impairment. Specifically, a positive smoking history elevated FVC 
and reduced Kco by 6%, results which are very similar to that noted in a 
contemporaneous study evaluating the effects of smoking and emphysema in 
scleroderma.37 However a report by Wells et al 1 demonstrated that after correcting 
for the presence of emphysema, smoking status had no independent effect on 
pulmonary function impairment. Though a smoking history would at first appear at 
odds with FVC elevation and Kco retardation the effects might simply reflect a link 
with emphysema secondary to smoking. As visual evaluation of a CT may only 
capture a proportion of the emphysema present within the lungs, the emergence of 
a statistically significant smoking history may indicate that emphysema extent has 
been underestimated by visual scores; a phenomenon that appears greatest at 
extremes of emphysema extent.  
 
There were some limitations to the current study. Histopathological proof of an IPF 
diagnosis was lacking in the majority of patients, but all cases were reviewed 
according to current diagnostic and treatment guidelines 19 in what is now the 
accepted standard of an MDT setting. Distinguishing admixed emphysema from 
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honeycomb cysts is associated with poor inter-observer agreement, 38 and may have 
limited the reliability with which the emphysema extent was visually characterized. 
However the negative correlations between the admixed emphysema scores and the 
FEV1/FVC ratio, indicate that for the most part, honeycomb cysts were not being 
misclassified as emphysema.  
 
In conclusion, we have demonstrated that it is baseline disease severity that 
determines outcome in a patient with IPF and that co-existing emphysema does not 
have an additional negative impact on outcome. We have demonstrated that DLco, 
by capturing the effects of both interstitial damage and emphysema is the optimal 
measure of disease severity when emphysema co-exists with fibrosis. Our study has 
also highlighted the physiological subtleties that develop when emphysema is both 
isolated from and admixed within areas of fibrosis.  
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Variable Group 1 
No emphysema  
(n=167 unless 
stated) 
Group 2 
Visual Emphysema  
(n=105 unless 
stated) 
Group 
Comparison  Units are percentage 
 unless stated 
Median Age (years) 67 66 =0.05* 
Male/female (ratio) 126/41  85/20  =0.29* 
Survival (alive/dead) 49/118 22/83 =0.15* 
Never/ever-smokers (ratio) 82/85 14/91 <0.0001* 
Pack year history (years) 21.0 ± 14.6 (80) 35.0 ± 24.2 (84) <0.0001^ 
Lung Cancer prevalence 1.2 9.5 =0.001* 
FEV1 % predicted  67.7 ± 19.3 (149) 75.5 ± 17.8 (101) =0.002^ 
FVC % predicted  62.9 ± 19.1 (149) 76.8 ± 19.1 (101) <0.0001^ 
FEV1/FVC % predicted 108.4 ± 8.8 (149) 100.0 ± 12.8 (101) <0.0001^ 
DLco % predicted 36.7 ± 13.4 (150) 35.6 ± 12.0 (97) =0.52^ 
Kco % predicted 74.8 ± 17.5 (150) 61.5 ± 18.6 (97) <0.0001^ 
TLC% predicted 59.0 ± 14.3 (143) 70.2 ± 15.7 (96) <0.0001^ 
CPI 57.0 ± 11.7 (146) 52.4 ± 10.5 (92) =0.001^ 
CALIPER ILD extent  29.3 ± 18.5 21.9 ± 16.2 =0.001^ 
Visual ILD extent  49.3 ± 17.7 44.0 ± 18.8 =0.02^ 
Visual TxBx   7.6 ± 3.2   6.5 ± 3.2 =0.008^ 
 
Table 1. Characteristics of IPF patients with and without emphysema. Variables 
examined include: patient demographic details and measures of pulmonary function 
indices, CALIPER and visually scored CT parameters. Data represent mean values 
with standard deviations unless otherwise stated. Significant differences between 
mean ranks of the two groups were calculated using the Chi-Square test for 
categorical independent variables (*) and the T test for continuous variables (^). 
FEV1 = forced expiratory volume in one second, FVC = forced vital capacity, DLco = 
diffusing capacity for carbon monoxide, Kco=carbon monoxide transfer coefficient, 
TLC=total lung capacity, CPI=composite physiologic index, ILD=interstitial lung 
disease, TxBx=traction bronchiectasis, NS=not significant.   
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 Pulmonary 
function test 
CT Pattern  Beta 
Coefficient 
95% Confidence 
Interval 
P value Model R2 
Visual ILD 
and 
emphysema 
evaluation  
FVC Emphysema  0·48  0·28, 0·68 <0·0001 0·38 
ILD extent -0·49 -0·60, -0·38 <0·0001 
DLco Emphysema -0·34 -0·45, -0·22 <0·0001 0·49 
 ILD extent -0·49 -0·55, -0·42 <0·0001 
Kco Emphysema -0.88 -1.06, -0.70 <0·0001 0.44 
 ILD extent -0.42 -0.53, -0.42 <0·0001  
CPI Emphysema -0.02 -0.12, 0.09    0.76 0·47 
 ILD extent  0·44  0·37, 0·50 <0·0001 
CALIPER ILD 
and visual 
emphysema 
evaluation 
FVC Emphysema  0.31  0.13, 0.49    0.001 0·52 
ILD extent -0.67 -0·77, -0·57 <0·0001  
DLco Emphysema -0·44 -0·56, -0.32 =0·0001 0·44 
 ILD extent -0·49 -0·56, -0·41 <0·0001 
Kco Emphysema -0.91 -1.10, -0.71 <0·0001 0.33 
 ILD extent -0.23 -0.35, -0.11   0·0002  
CPI Emphysema 0.09 -0.02, 0.19   0.10 0·50 
 ILD extent  0·47  0·41, 0·54 <0·0001 
 
Table 2. Relationships between pulmonary function indices (FVC, DLco, Kco and CPI) and 
visual and CALIPER interstitial lung disease extents and visual emphysema extent 
calculated using multivariate linear regression. The table is similar to Table 6, but instead 
of evaluating thresholds of emphysema, total emphysema extent was analysed in each 
model. All CT variables were calculated as a percent of total lung volume. In all models, 
adjustment was made for patient age, gender and smoking status (never vs ever). CT= 
Computed tomography, FVC=forced vital capacity, DLco=diffusing capacity for carbon 
monoxide, Kco= carbon monoxide transfer coefficient, CPI=composite physiological index, 
ILD=interstitial lung disease.  
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PFT CALIPER ILD extent 
(percent) 
Visual emphysema 
threshold 
Smoking status 
(never vs ever) 
Equation 
R2 
FVC -0.7 (-0.8,-0.6) p<0.0001  7.7 (3.8,11.7) p=0.0001  5.2 (1.5,8.9) p=0.006 0.53 
DLco -0.5 (-0.5,-0.4) p<0.0001 -5.0 (-7.9,-2.0) p=0.001 -0.0 (-2.7,2.7) p=0.99 0.36 
Kco -0.2 (-0.3,-0.1) p=0.005 -13.5 (-18.4,-8.7) p<0.0001 -4.8 (-9.3,-0.3) p=0.04 0.20 
CPI  0.5 (0.4,0.5) p<0.0001 -0.1 (-2.5,2.2) p=0.92 -1.5 (-3.7,0.7) p=0.18 0.49 
FVC -0.7 (-0.8,-0.6) p<0.0001  9.0 (4.2,13.9) p=0.0003  5.9 (2.3,9.5) p=0.001 0.52 
DLco -0.5 (-0.5,-0.4) p<0.0001 -10.3 (-13.7,6.9) p<0.0001 -0.5 (-2.0,3.0) p=0.70 0.41 
Kco -0.2 (-0.3,-0.1) p=0.001 -23.4 (-29.0,-17.9) p<0.0001 -4.4 (-8.5,-0.3) p=0.04 0.31 
CPI  0.5 (0.4,0.5) p<0.0001 -1.9 (-0.9,4.8) p=0.19 -1.9 (-4.1,0.2) p=0.07 0.49 
FVC -0.7 (-0.8,-0.6) p<0.0001  10.2 (4.7,15.7) p=0.0003  6.1 (2.5,9.7) p=0.001 0.52 
DLco -0.5 (-0.5,-0.4) p<0.0001 -11.7 (-15.6,-7.8) p<0.0001 -0.3(-2.3,2.8) p=0.83 0.41 
Kco -0.2 (-0.3,-0.1) p=0.002 -25.2 (-31.5,-18.9) p<0.0001 -5.2 (-9.3,-1.0) p=0.02 0.29 
CPI  0.5 (0.4,0.5) p<0.0001 -2.2 (-1.1, 5.4) p=0.91 -1.9 (-4.0,0.2) p=0.08 0.49 
 
Table 3. The independent effects of CALIPER ILD extent and thresholds of visual 
emphysema on various pulmonary function indices (FVC, DLco, Kco, CPI). In all models 
adjustment was made for patient age, gender and smoking status (never vs ever). 
Emphysema extent thresholds that were examined included: >0% visual emphysema 
(white), >5% visual emphysema (light grey), >10% visual emphysema (dark grey). CALIPER 
ILD extent was quantified as a percentage of the lung; emphysema was categorized as 
presence above the relevant threshold; smokers were categorized as never or ever 
smokers. PFT=pulmonary function test, FEV1 = forced expiratory volume in one second, 
FVC = forced vital capacity, DLco = diffusing capacity for carbon monoxide, Kco=carbon 
monoxide transfer coefficient, ILD=interstitial lung disease.  
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PFT CT Pattern  Beta 
Coefficient 
95% Confidence 
Interval 
P value Model R2 
FVC Isolated Emphysema 0.20 -0.22, 0.63   0.35 0·38 
Admixed Emphysema  0.73  0.36, 1.11 =0.0002 
ILD extent -0·51 -0·62, -0·39 <0·0001 
 Smoking status  6.30  1.88, 10.71   0.005  
DLco Isolated Emphysema -0·51 -0·75, -0·27 <0·0001 0·50 
 Admixed Emphysema -0.19 -0.40, 0.03   0.09 
 ILD extent -0·50 -0·57, -0·43 <0·0001 
 Smoking status -0.11 -2.64, 2.43   0.94  
Kco Isolated Emphysema -1.01 -1.39, -0.63 <0·0001 0.44 
 Admixed Emphysema -0.79 -1.12, -0.45 <0.0001  
 ILD extent -0.43 -0.54, -0.32 <0·0001  
 Smoking status -5.70 -9.68, -1.41   0·005  
VA Isolated Emphysema 0.15 -0.16, 0.46   0.35 0·38 
 Admixed Emphysema  0.48  0.20, 0.76  =0·001 
 ILD extent -0·43 -0.52, -0·35 <0·0001 
 Smoking status  3.86  0.60, 7·11  =0.02  
 
Table 4. Associations between subtypes of emphysema (percentage of the lung 
comprising emphysema separate to or admixed with fibrosis) and various lung function 
indices (FVC, DLco, Kco and VA) examined using multivariate linear regression. For 
example, only isolated emphysema and not admixed emphysema was associated with 
DLco in a combined model. All models were adjusted for baseline visual interstitial lung 
disease (ILD) extent as a percentage of the lung, age, gender and smoking status (never vs 
ever). ILD and emphysema extents were calculated as a percent of total lung volume. 
PFT=pulmonary function test, CT= Computed tomography, FVC=forced vital capacity, 
DLco=diffusing capacity for carbon monoxide, Kco= carbon monoxide transfer coefficient, 
VA=alveolar volume. 
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 CT Pattern  Beta 
Coefficient 
95% Confidence 
Interval 
P value Model R2 
Visual Emphysema extent -0.06 -0.09, -0.03 <0.0001 0·51 
Honeycombing  0.10  0.07, 0.12 <0.0001 
ILD extent  0·06  0·05, 0·08 <0·0001 
Visual Isolated Emphysema -0.07 -0.13, -0.01   0.02 0.51 
 Admixed Emphysema -0.06 -0.11, -0.00   0.04  
 Honeycombing  0.10  0.07, 0.12 <0.0001  
 ILD extent  0·06  0·05, 0·08 <0·0001  
CALIPER Emphysema extent* -0.10 -0.14, -0.07 <0.0001 0·36 
 Honeycombing  0.84  0.64, 1.05 <0·0001 
 ILD extent  0·06  0·04, 0·07 <0·0001 
 
Table 5. Visually and CALIPER scored CT determinants of traction bronchiectasis 
severity evaluated using multivariate linear regression. For example visually scored 
emphysema extent, ILD extent and honeycombing extent all expressed as a 
percentage of the lung were all independently associated with traction 
bronchiectasis severity. All models were adjusted for patient age, gender and 
smoking status (never vs ever). *Emphysema was only quantified visually. CT= 
Computed tomography, ILD=interstitial lung disease.  
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Baseline variables Hazard 
ratio 
P Value 95.0% Confidence 
Interval 
Lower Upper 
Visual Emphysema (continuous) 1.01   0.18 1.00 1.02 
Visual Emphysema (categorical) 1.10   0.17 0.96 1.25 
Visual Emphysema (presence) 1.18   0.26 0.89 1.56 
Visual ILD extent 1.03 <0.0001 1.02 1.04 
CALIPER Emphysema 1.00   0.84 0.98 1.03 
CALIPER ILD extent 1.03 <0.0001 1.03 1.04 
CILDemph 1.03 <0·0001 1.03 1.04 
VILDemph 1.02 <0.0001 1.02 1.03 
FVC 1.07 <0·0001 1.06 1.08 
DLco 1.04 <0·0001 1.03 1.05 
CPI 1.07 <0.0001 1.05 1.08 
 
Table 6. Univariate CALIPER and visually derived CT variables and pulmonary 
function indices predictive of mortality using Cox proportional hazards regression 
models. Visual emphysema was scored as a continuous variable, as a 4-point 
categorical variable (0=no emphysema, 1=0-5% emphysema, 2=5-15% emphysema, 
>15% emphysema) and as a binary, absence-presence variable. ILD=interstitial lung 
disease, CILDemph=summed total of CALIPER ILD extent and visual emphysema 
extent, VILDemph= summed total of visual ILD extent and visual emphysema extent, 
FVC=forced vital capacity, DLco=diffusing capacity for carbon monoxide, 
CPI=composite physiologic index. 
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Patient subset 
Baseline severity and 
emphysema models 
Hazard 
ratio 
P Value 95.0% Confidence 
Interval 
Lower Upper 
All patients Visual Emphysema categorical 1.23 =0.006 1.06 1.43 
CALIPER ILD extent 1.04 <0·0001 1.03 1.04 
Visual Emphysema categorical 1.13   0.09 1.08 1.31 
Visual ILD extent 1.03 <0·0001 1.02 1.04 
Model 1 CILDemph 1.03 <0.0001 1.03 1.04 
Visual Emphysema presence 0.93   0.67 0.68 1.29 
Model 2 VILDemph 1.03 <0.0001 1.02 1.03 
 Visual Emphysema presence 0.94   0.73 0.68 1.30 
Model 3 DLco 0.94 <0·0001 0.93 0.95 
Visual Emphysema presence 0.98   0.93 0.71 1.37 
Model 1 
CILDemph 1.03 <0·0001 1.03 1.04 
Visual Emphysema categorical 0.91   0.20 0.78 1.05 
Model 2 VILDemph 1.03 <0.0001 1.02 1.04 
Visual Emphysema categorical 0.88   0.11 0.75 1.03 
Model 3 
DLco 0.94 <0.0001 0.93 0.95 
Visual Emphysema categorical 0.97   0.68 0.83 1.13 
 
Table 7. Multivariate Cox proportional hazards regression models. In an examination 
of all patients in the cohort (n=272), baseline ILD extent scored using CALIPER and 
visual assessment were separately evaluated in models against visual emphysema 
extent. Visual emphysema was scored as a 4-point categorical variable (0=no 
emphysema, 1=0-5% emphysema, 2=5-15% emphysema, >15% emphysema). In a 
separate subanalysis of patients with severe/end stage disease (n=130/272), two 
morphological measures of baseline disease severity were analysed. The first 
represented the combination of visual emphysema scores with CALIPER-derived ILD 
extent: CILDemph (Model 1) and the second represented the combination of visual 
emphysema scores with visually-derived ILD extent: VILDemph (Model 2). A third 
measure of baseline disease severity was a functional severity measure: DLco (Model 
3). To evaluate whether the presence of emphysema had any impact on outcome 
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after adjusting for total baseline disease severity, all three models were separately 
evaluated alongside the presence of emphysema and the four-point categorical 
emphysema score. All models were adjusted for patient age, gender and smoking 
status (never vs ever).  
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Figure 1. Axial CT images and colour overlay images demonstrating quantitation of 
parenchymal patterns by CALIPER in a 71-year-old male ex-40-pack-year smoker 
diagnosed with IPF. CT images (a+c) demonstrate severe emphysema in the upper 
lobes, and fibrosis characterized primarily by reticular pattern and traction 
bronchiectasis in the lower lobes, with an emphysematous bulla in the left lower 
lobe. On visual scoring, 40% of the lung was characterized as emphysema, whilst 
31% was identified as interstitial lung disease. The CALIPER overlay images (b+d) 
outline emphysema (light and dark blue) in the upper lobes, quantified as 23% of the 
lung volume. The sum of ground glass opacities (yellow), reticular pattern (orange) 
and honeycombing (brown) constitute total interstitial lung disease extent which 
was quantified as 7.5% of the lung. CALIPER defines light and dark green areas as 
normal lung. 
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Figure 2a. Kaplan Meier survival curves were not found to be significantly different in 
outcome between IPF patients without any visually scored emphysema on CT (blue; 
n=167, restricted mean survival=36.5±2.3), and IPF patients with emphysema scored 
visually on CT (green; n=105, restricted mean survival=32.0±2.5). Log rank test 
p=0.20. 
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Figure 2b. Kaplan Meier survival curves were not found to be significantly different in 
outcome between IPF patients with a baseline DLco<35 without any visually scored 
emphysema on CT (blue; n=79, restricted mean survival=20.9±1.8), and IPF patients 
with emphysema scored visually on CT (green; n=51, restricted mean 
survival=21.8±2.9). Log rank test p=0.84. 
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